Any clinical trials looking into synergistic effects of blocking SMAD and MAPK pathways should select agents that target both ALK4 and ALK5 and consider using them for short intervals because of the potential tumor-promoting effects of SMAD inhibition in cancer. The gene discussed is TGFBR1; the disease is neoplasm.